This site is intended for Healthcare professionals only.

Alembic Pharmaceuticals Q1FY18 consolidated net profit declines 39 per cent yoy

Alembic Pharmaceuticals Q1FY18 consolidated net profit declines 39 per cent yoy

Alembic Pharmaceuticals consolidated revenue for the quarter came in at Rs. 648 crore, registering 12% yoy decline.

This was driven by 21% yoy decrease in revenue from India formulation business. It has also registered de-growth of 8.7% yoy in its international formulation business.

EBITDA for the quarter fell by 35.7% yoy to Rs. 101 crore with a corresponding margin contraction of 571 bps. EBITDA margin for the quarter stood at 15.6%. This margin contraction was driven by increase in purchase of stock in trade and employee benefit expenses by 50% yoy and 18% yoy respectively.

The PAT for the quarter came in at Rs. 63 crore, yoy decline of 39%.

During the quarter, Q1FY18, company has received 6 ANDA (Abbreviated New Drug Application), cumulative ANDA approvals at 58.



Source: PRESS RELEASE
0 comment(s) on Alembic Pharmaceuticals Q1FY18 consolidated net profit declines 39 per cent yoy

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted